As global markets navigate a landscape marked by mixed performances and economic uncertainties, investors are increasingly looking for opportunities that can offer potential growth at lower price points. Penny stocks, though often seen as a niche area, continue to present intriguing possibilities for those willing to explore smaller or newer companies with strong financial health. In this article, we will highlight three Asian penny stocks that exemplify the potential for significant returns when solid fundamentals align with market opportunity.
Top 10 Penny Stocks In Asia
| Name | Share Price | Market Cap | Rewards & Risks |
| Lever Style (SEHK:1346) | HK$1.48 | HK$927.78M | ✅ 4 ⚠️ 1 View Analysis > |
| Advice IT Infinite (SET:ADVICE) | THB4.98 | THB3.09B | ✅ 3 ⚠️ 2 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.49 | HK$2.07B | ✅ 4 ⚠️ 1 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD1.06 | SGD429.61M | ✅ 4 ⚠️ 2 View Analysis > |
| T.A.C. Consumer (SET:TACC) | THB4.94 | THB2.96B | ✅ 3 ⚠️ 3 View Analysis > |
| Atlantic Navigation Holdings (Singapore) (Catalist:5UL) | SGD0.10 | SGD52.35M | ✅ 2 ⚠️ 4 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.39 | SGD13.34B | ✅ 5 ⚠️ 1 View Analysis > |
| Anton Oilfield Services Group (SEHK:3337) | HK$0.94 | HK$2.52B | ✅ 3 ⚠️ 2 View Analysis > |
| Livestock Improvement (NZSE:LIC) | NZ$1.04 | NZ$148.04M | ✅ 2 ⚠️ 5 View Analysis > |
| Scott Technology (NZSE:SCT) | NZ$2.80 | NZ$239.67M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 949 stocks from our Asian Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
Zhongzhu Healthcare HoldingLtd (SHSE:600568)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Zhongzhu Healthcare Holding Co., Ltd is involved in the research, development, production, and sale of drugs in China with a market cap of CN¥4.40 billion.
Operations: The company generates revenue of CN¥570.62 million from its operations in China.
Market Cap: CN¥4.4B
Zhongzhu Healthcare Holding Co., Ltd, with a market cap of CN¥4.40 billion and revenue of CN¥570.62 million, remains unprofitable despite reducing its net loss from CNY 92.42 million to CNY 33.79 million over the past year. The company has no debt and maintains a strong cash position with sufficient runway for over three years due to positive free cash flow growth. However, challenges include a negative return on equity and an inexperienced board with an average tenure of just 1.5 years, potentially impacting strategic direction amidst ongoing financial recovery efforts.
- Navigate through the intricacies of Zhongzhu Healthcare HoldingLtd with our comprehensive balance sheet health report here.
- Evaluate Zhongzhu Healthcare HoldingLtd's historical performance by accessing our past performance report.
Infund Holding (SZSE:002141)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Infund Holding Co., Ltd. operates in China, focusing on the production of micro enameled wire and veterinary vaccines, with a market cap of CN¥4.15 billion.
Operations: Infund Holding Co., Ltd. has not reported any specific revenue segments.
Market Cap: CN¥4.15B
Infund Holding Co., Ltd., with a market cap of CN¥4.15 billion, has shown significant revenue growth, reporting CN¥931.04 million in sales for the nine months ended September 2025 compared to CN¥45.55 million the previous year. The company achieved a net income of CN¥42.28 million during this period, reflecting improved financial performance despite its unprofitability history. Infund Holding's short-term assets significantly exceed both its short and long-term liabilities, indicating strong liquidity. Its board is experienced with an average tenure of six years, although it faces challenges such as less than one year of cash runway and negative return on equity at -9.7%.
- Click here to discover the nuances of Infund Holding with our detailed analytical financial health report.
- Explore historical data to track Infund Holding's performance over time in our past results report.
Shenzhen Hemei GroupLTD (SZSE:002356)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Shenzhen Hemei Group Co., LTD. operates in the sale of clothing and accessories both in China and internationally, with a market cap of CN¥5.05 billion.
Operations: No specific revenue segments are reported for Shenzhen Hemei Group Co., LTD.
Market Cap: CN¥5.05B
Shenzhen Hemei Group Co., LTD., with a market cap of CN¥5.05 billion, has demonstrated substantial financial improvement, reporting sales of CN¥456.02 million for the nine months ending September 2025 compared to CN¥157.14 million a year earlier, and achieving profitability with a net income of CN¥51.75 million. The company is debt-free and maintains strong liquidity as its short-term assets significantly exceed its liabilities. Despite the relatively inexperienced board with an average tenure of 2.8 years, Shenzhen Hemei's recent transition to profitability marks a positive shift in its financial trajectory within the specialty retail sector.
- Click to explore a detailed breakdown of our findings in Shenzhen Hemei GroupLTD's financial health report.
- Learn about Shenzhen Hemei GroupLTD's historical performance here.
Make It Happen
- Explore the 949 names from our Asian Penny Stocks screener here.
- Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Infund Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com